Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy of the Oncoxin-Viusid® Nutritional Supplement on the Quality of Life of Patients With Advanced or Metastatic Ovarian Epithelial Cancer. Clinical Trial Phase II.

NCT03562897 is registered in ClinicalTrials.gov with Catalysis SL as lead sponsor.

NCT NCT03562897
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03562897 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy of the Oncoxin-Viusid® Nutritional Supplement on the Quality of Life of Patients With Advanced or Metastatic Ovarian Epithelial Cancer. Clinical Trial Phase II.
Lead sponsor
Catalysis SL
Phase
Phase 2
Overall status
Completed
Start date
October 25, 2018
Completion date
June 15, 2022
Enrollment
40 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adnexal diseases, carcinoma, endocrine gland neoplasm, endocrine system diseases, female urogenital diseases, female urogenital diseases and pregnancy complications, genital diseases, female, genital neoplasm, female, gonadal disorders, neoplasms, glandular and epithelial, ovarian diseases, ovarian neoplasm, urogenital neoplasms